[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338180-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338180-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","claudin-1-4-6-and-18-isoform-2-as-targets-for-the-treatment-of-cancer-review","Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer - Review","","The review surveys claudin (CLDN) isoform biology and cancer relevance, focusing on CLDN1, CLDN4, CLDN6, and CLDN18.2. Claudins are tight-junction tetraspan proteins whose cancer-associated upregulation enables targeted therapies. The article discusses investigational clinical-trial drugs, highlighting cLdN18.2-directed treatments such as zolbetuximab and osemitamab, plus ADCs and bispecific antibodies or CAR T-cell approaches. It also summarizes reported response rates and advances, and outlines future research directions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/claudin-1-4-6-and-18-isoform-2-as-targets-for-the-treatment-of-cancer-review/338180/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/claudin-1-4-6-and-18-isoform-2-as-targets-for-the-treatment-of-cancer-review/338180.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which claudin isoforms are emphasized as cancer therapy targets in this review?","Question",{"text":63,"@type":64},"The review focuses on cLdN1-, cLdN4-, cLdN6- and cLdN18.2-targeting investigational drugs in clinical trials.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What therapeutic modalities are discussed for targeting CLDN isoforms?",{"text":68,"@type":64},"The review covers CLDN-targeting monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and CLDN-directed CAR T cells.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is CLDN18.2 therapy highlighted as the most advanced area?",{"text":72,"@type":64},"cLdN18.2-directed therapy for gastric and other cancers is described as the most advanced, supported by clinical results for agents such as zolbetuximab and osemitamab, including survival benefits in combination regimens.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338180,1790517428,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","INTERNATIONAL JOURNAL OF MOLEcULAR MEdIcINE 54: 100, 2024  \nClaudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)  \nMASUKO KATOH 1 and MASARU KATOH 1,2  \n1  \ndepartment of Global Network, M & M Precision Medicine, Tokyo 113‑0033, Japan; department of Omics Network, National cancer center, Tokyo 104‑0045, Japan  \n2  \nReceived July 24, 2024; Accepted September 4, 2024  \ndOI: 10.3892/ijmm.2024.5424  \nAbstract. The 24 claudin (CLDN) genes in the human genome encode 26 representative cLdN family proteins. cLdNs are tetraspan‑transmembrane proteins at tight junctions. Because several cLdN isoforms, such as cLdN6 and cLdN18 . 2, are specifically upregulated in human cancer, CLDN‑targeting monoclonal antibodies (mAbs), antibody‑drug conjugates (ADCs), bispecific antibodies (bsAbs) and chimeric antigen receptor (cAR) T cells have been developed. In the present review, cLdN1‑, 4‑, 6‑ and 18.2‑targeting investigational drugs in clinical trials are discussed. cLdN18.2‑directed therapy for patients with gastric and other types of cancer is the most advanced area in this field. The mouse/human chimeric anti‑cLdN18.2 mAb zolbetuximab has a single‑agent objec‑ tive response rate (ORR) of 9%, and increases progression‑free and overall survival in combination with chemotherapy. The human/humanized anti‑cLdN18 .2 mAb osemitamab, and Adcs AZd0901, IBI343 and LM‑302, with single‑agent ORRs of 28‑60%, have been tested in phase III clinical trials. In addition, bsAbs, cAR T cells and their derivatives targeting cLdN4, 6 or 18.2 are in phase I and/or II clinical trials . AZd0901, IBI343, zolbetuximab and the anti‑cLdN1 mAb ALE.c04 have been granted fast track designation or priority review designation by the US Food and drug Administration.  \nContents  \n1. Introduction  \n2. cLdN1‑targeted therapy  \n3. cLdN4‑targeted therapy  \nCorrespondence to: dr Masaru Katoh, department of Omics Network, National cancer center, 5‑1‑1 Tsukiji, chuo, Tokyo 104‑0045, Japan  \nE‑mail: mkatoh‑[kkr@umin.ac.jp](kkr@umin.ac.jp)  \nKey words: epithelial‑mesenchymal transition, fibroblast growth factor receptor, intratumor heterogeneity, immunosuppressive tumor microenvironment, non‑small cell lung cancer, ovarian cancer, pancreatic cancer, splicing variant, TGF‑β, WNT  \n4. cLdN6‑targeted therapy  \n5. cLdN18.2‑targeted therapy  \n6. Future research directions  \n7. conclusion  \n1. Introduction  \nThe human claudin (CLDN) gene family consists of the CLDN1‑12, 14‑20, 22‑25 and 34 genes (1‑4). The CLDN10 gene encodes the cLdN10a and cLdN10b isoforms, expressed under control of renal/uterine and ubiquitous promoters, respectively (5). The CLDN18 gene encodes cLdN18.1 and cLdN18.2 isoforms, expressed under the control of pulmonary and gastric promoters, respectively (6). Therefore, the 24 human CLDN genes encode 26 representative full‑length cLdN proteins (Table I).  \ncLdN isoforms at intercellular tight junctions have four transmembrane domains. The first extracellular folding loop stabilizes the paracellular interface and the c‑terminal cyto‑ plasmic region interacts with the zona occludens 1 scaffold protein for the assembly of other tight junction proteins (7,8) . cLdN proteins that form homo‑ and heterotypical as well as trans/cis complexes regulate paracellular barrier or perme‑ ability functions at endothelial, epidermal, gastrointestinal, renal and other interfaces to maintain organ and/or whole‑body homeostasis (9‑15) . Tight junction functions are dynami‑ cally regulated by junctional cLdN isoforms that undergo antegrade transport from the Golgi apparatus to the plasma membrane, endocytosis to early endosomes, and sorting to recycling endosomes for trafficking back to the cell surface or late endosomes for lysosomal degradation (Fig. 1) .  \nGermline mutations in human CLDN genes have been reported in patients with non‑cancerous diseases (Table I) . CLDN1 mutations are related to ichthyosis, leukocyte vacu‑ oles, alopecia and sclerosing cholangitis ","cbCaigDcAwaXTpNh","https://ap.wps.com/l/cbCaigDcAwaXTpNh","pdf",2441469,13,"English","# Introduction\n# CLDN1-targeted therapy\n# CLDN4-targeted therapy\n# CLDN6-targeted therapy\n# CLDN18.2-targeted therapy\n# Future research directions\n# Conclusion","[{\"question\":\"Which claudin isoforms are emphasized as cancer therapy targets in this review?\",\"answer\":\"The review focuses on cLdN1-, cLdN4-, cLdN6- and cLdN18.2-targeting investigational drugs in clinical trials.\"},{\"question\":\"What therapeutic modalities are discussed for targeting CLDN isoforms?\",\"answer\":\"The review covers CLDN-targeting monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and CLDN-directed CAR T cells.\"},{\"question\":\"Why is CLDN18.2 therapy highlighted as the most advanced area?\",\"answer\":\"cLdN18.2-directed therapy for gastric and other cancers is described as the most advanced, supported by clinical results for agents such as zolbetuximab and osemitamab, including survival benefits in combination regimens.\"}]","Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer - Review | PDF",1790022392,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e77a0e3c9ad214025b96f1025784548a.webp",983,1357,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a07c0c171888eb3cd0eabd1a56edda18.webp",982,1356,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f60eae5ad3e681c8b24a320611565cf.webp",981,1354,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92061918c36e9563dab627f332692d68.webp",980,1353]